Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-279-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$694.02 million
Profitability
Miscellaneous
Employees2,191
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) released its earnings results on Thursday, August, 1st. The company reported ($0.02) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.09. The firm earned $178 million during the quarter, compared to analyst estimates of $171.97 million. Akorn had a negative net margin of 72.25% and a negative return on equity of 17.88%. The company's quarterly revenue was down 6.8% on a year-over-year basis. View Akorn's Earnings History.
When is Akorn's next earnings date?
How can I listen to Akorn's earnings call?
Akorn will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Akorn issued on next quarter's earnings?
Akorn updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $690-710 million, compared to the consensus revenue estimate of $692.99 million.
What price target have analysts set for AKRX?
4 brokerages have issued 12-month price objectives for Akorn's shares. Their predictions range from $4.00 to $11.00. On average, they anticipate Akorn's stock price to reach $7.00 in the next year. This suggests a possible upside of 48.9% from the stock's current price. View Analyst Price Targets for Akorn.
What is the consensus analysts' recommendation for Akorn?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.
Has Akorn been receiving favorable news coverage?
News articles about AKRX stock have trended negative on Thursday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Akorn earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Akorn.
Are investors shorting Akorn?
Akorn saw a decrease in short interest in September. As of September 30th, there was short interest totalling 10,920,000 shares, a decrease of 13.0% from the August 30th total of 12,550,000 shares. Based on an average daily volume of 1,920,000 shares, the short-interest ratio is presently 5.7 days. Approximately 11.6% of the shares of the stock are sold short. View Akorn's Current Options Chain.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Deciphera Pharmaceuticals (DCPH), Tricida (TCDA), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT), Uniqure (QURE), Alder Biopharmaceuticals (ALDR), Insmed (INSM), Aimmune Therapeutics (AIMT), Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV) and Supernus Pharmaceuticals (SUPN).
What other stocks do shareholders of Akorn own?
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
- Dr. Bruce Kutinsky, Consultant (Age 53)
- Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)
Who are Akorn's major shareholders?
Akorn's stock is owned by many different of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.18%), State of Alaska Department of Revenue (0.06%), Nisa Investment Advisors LLC (0.03%) and CIBC Private Wealth Group LLC (0.01%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.
Which major investors are selling Akorn stock?
Which major investors are buying Akorn stock?
AKRX stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Nisa Investment Advisors LLC and CIBC Private Wealth Group LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $4.70.
How big of a company is Akorn?
Akorn has a market capitalization of $591.50 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.
What is Akorn's official website?
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
